UNICHEM LAB | NOVARTIS | UNICHEM LAB/ NOVARTIS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -47.2 | 2,073.7 | - | View Chart |
P/BV | x | 1.2 | 27.5 | 4.2% | View Chart |
Dividend Yield | % | 1.2 | 1.6 | 74.4% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
UNICHEM LAB Mar-19 |
NOVARTIS Mar-19 |
UNICHEM LAB/ NOVARTIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 292 | 980 | 29.8% | |
Low | Rs | 182 | 600 | 30.3% | |
Sales per share (Unadj.) | Rs | 167.7 | 198.7 | 84.4% | |
Earnings per share (Unadj.) | Rs | -3.6 | 21.0 | -17.3% | |
Cash flow per share (Unadj.) | Rs | 5.9 | 22.3 | 26.7% | |
Dividends per share (Unadj.) | Rs | 4.00 | 10.00 | 40.0% | |
Dividend yield (eoy) | % | 1.7 | 1.3 | 133.4% | |
Book value per share (Unadj.) | Rs | 372.3 | 307.5 | 121.1% | |
Shares outstanding (eoy) | m | 70.38 | 24.69 | 285.1% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 1.4 | 4.0 | 35.6% | |
Avg P/E ratio | x | -65.3 | 37.7 | -173.2% | |
P/CF ratio (eoy) | x | 39.9 | 35.5 | 112.4% | |
Price / Book Value ratio | x | 0.6 | 2.6 | 24.8% | |
Dividend payout | % | -110.2 | 47.7 | -231.0% | |
Avg Mkt Cap | Rs m | 16,680 | 19,508 | 85.5% | |
No. of employees | `000 | 2.6 | 0.6 | 447.8% | |
Total wages/salary | Rs m | 2,393 | 1,171 | 204.4% | |
Avg. sales/employee | Rs Th | 4,535.2 | 8,445.4 | 53.7% | |
Avg. wages/employee | Rs Th | 919.8 | 2,015.7 | 45.6% | |
Avg. net profit/employee | Rs Th | -98.2 | 891.0 | -11.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 11,801 | 4,907 | 240.5% | |
Other income | Rs m | 984 | 783 | 125.7% | |
Total revenues | Rs m | 12,785 | 5,689 | 224.7% | |
Gross profit | Rs m | -835 | 123 | -679.9% | |
Depreciation | Rs m | 674 | 32 | 2,118.6% | |
Interest | Rs m | 75 | 16 | 473.0% | |
Profit before tax | Rs m | -600 | 858 | -69.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -343 | 340 | -101.0% | |
Profit after tax | Rs m | -256 | 518 | -49.4% | |
Gross profit margin | % | -7.1 | 2.5 | -282.7% | |
Effective tax rate | % | 57.3 | 39.6 | 144.5% | |
Net profit margin | % | -2.2 | 10.6 | -20.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 20,384 | 8,055 | 253.1% | |
Current liabilities | Rs m | 5,029 | 1,850 | 271.8% | |
Net working cap to sales | % | 130.1 | 126.4 | 102.9% | |
Current ratio | x | 4.1 | 4.4 | 93.1% | |
Inventory Days | Days | 105 | 45 | 232.7% | |
Debtors Days | Days | 135 | 34 | 397.7% | |
Net fixed assets | Rs m | 9,023 | 150 | 6,023.6% | |
Share capital | Rs m | 141 | 123 | 114.1% | |
"Free" reserves | Rs m | 26,058 | 7,469 | 348.9% | |
Net worth | Rs m | 26,199 | 7,592 | 345.1% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 31,496 | 9,824 | 320.6% | |
Interest coverage | x | -7.0 | 54.9 | -12.7% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.4 | 0.5 | 75.0% | |
Return on assets | % | -0.6 | 5.4 | -10.5% | |
Return on equity | % | -1.0 | 6.8 | -14.3% | |
Return on capital | % | -2.0 | 11.5 | -17.4% | |
Exports to sales | % | 69.4 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 8,188 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 8,188 | 58 | 14,215.3% | |
Fx outflow | Rs m | 596 | 1,326 | 44.9% | |
Net fx | Rs m | 7,592 | -1,269 | -598.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -3,278 | -1,943 | 168.7% | |
From Investments | Rs m | -2,860 | 2,742 | -104.3% | |
From Financial Activity | Rs m | -24 | -298 | 8.1% | |
Net Cashflow | Rs m | -4,690 | 501 | -935.6% |
Indian Promoters | % | 50.1 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 75.0 | - | |
Indian inst/Mut Fund | % | 15.1 | 2.0 | 755.0% | |
FIIs | % | 3.0 | 1.6 | 187.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 31.7 | 21.5 | 147.4% | |
Shareholders | 20,176 | 41,647 | 48.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare UNICHEM LAB With: IPCA LABS GSK PHARMA DR. DATSONS LABS PROCTER & GAMBLE HEALTH SANOFI INDIA
Compare UNICHEM LAB With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed a sharp sell-off today and ended deep in the red.
For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.
Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.
For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More